Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Minority Interest (2016 - 2018)

Historic Minority Interest for Coherus Oncology (CHRS) over the last 5 years, with Q2 2018 value amounting to -$1.3 million.

  • Coherus Oncology's Minority Interest fell 452.07% to -$1.3 million in Q2 2018 from the same period last year, while for Jun 2018 it was -$1.3 million, marking a year-over-year decrease of 452.07%. This contributed to the annual value of -$1.3 million for FY2017, which is 988.92% down from last year.
  • According to the latest figures from Q2 2018, Coherus Oncology's Minority Interest is -$1.3 million, which was down 452.07% from -$1.3 million recorded in Q1 2018.
  • Coherus Oncology's Minority Interest's 5-year high stood at -$44000.0 during Q4 2014, with a 5-year trough of -$1.3 million in Q2 2018.
  • Moreover, its 5-year median value for Minority Interest was -$1.1 million (2016), whereas its average is -$872250.0.
  • As far as peak fluctuations go, Coherus Oncology's Minority Interest crashed by 154090.91% in 2015, and later crashed by 452.07% in 2018.
  • Quarter analysis of 5 years shows Coherus Oncology's Minority Interest stood at -$44000.0 in 2014, then crashed by 1540.91% to -$722000.0 in 2015, then tumbled by 62.47% to -$1.2 million in 2016, then decreased by 9.89% to -$1.3 million in 2017, then dropped by 4.03% to -$1.3 million in 2018.
  • Its last three reported values are -$1.3 million in Q2 2018, -$1.3 million for Q1 2018, and -$1.3 million during Q4 2017.